Executive Summary
Overnight SEC filings from September 3-4, 2026, reveal a market bifurcated between high-conviction insider selling in growth/biotech names and significant corporate actions (M&A, spin-offs, restructurings). The most critical development is the FDA approval of Ionis Pharmaceuticals' ZANVASTRO for Alexander disease, a landmark event for an ultra-rare disorder, though offset by a mixed financial picture.
A wave of insider selling, particularly at Natera, Spyre Therapeutics, and Takeda, signals potential near-term tops in these high-flying names. Activist pressure is building at TransAct Technologies, while corporate restructuring dominates headlines with Flex's spin-off and The Trade Desk's 15% workforce reduction. The IPO litigation settlement at Rent the Runway and the de-registration of RE/MAX highlight ongoing post-IPO and M&A fallout. Overall, the data suggests a cautious tone from corporate insiders, offset by significant strategic catalysts in biotech and energy.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4 · Schedule 13D · DEFA14A · 8-K
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from September 03, 2026.
Investment Signals (10)
-
FDA approval of ZANVASTRO for Alexander disease is a massive catalyst for an ultra-rare disorder (1 in 1-3 million), creating a new revenue stream. However, FY2025 revenue declined 12% YoY, and the stock carries a Priority Review Voucher cost. [BULLISH/MIXED]
- Natera ↓ (BEARISH)▲
President of Clinical Diagnostics sold $4.96M in stock at ~$327, while CEO sold $545K. This is a significant insider liquidation at elevated prices, suggesting management sees limited near-term upside.
- Spyre Therapeutics ↓ (BEARISH)▲
CEO, CFO, and another executive collectively sold ~$3.8M in stock via 10b5-1 plans. The CFO sold 18,232 shares at $89.35, a high-volume liquidation from a key financial officer.
- Trade Desk ↓ (MIXED)▲
Announced a 15% workforce reduction to focus on high-priority growth. While a positive for long-term efficiency, the $39-51M restructuring charge in Q3 2026 is a significant near-term earnings headwind.
- TransAct Technologies ↓ (BULLISH)▲
Activist investor Charles Gillman (5.1% stake) is publicly agitating for a full sale of the company, citing undervaluation. This creates a clear catalyst for a potential premium buyout.
-
Chairman & CEO Sridhar KR exercised 9,688 options at $30.96 but also gifted 300,000 shares. The gift is a neutral signal, but the option exercise shows management is willing to invest cash into the stock. [NEUTRAL/BULLISH]
- Takeda Pharmaceutical ↓ (BEARISH)▲
President of R&D sold $2.15M in ADS at $18.49, a very large insider sale from a top executive. This is a strong bearish signal for the pharma giant.
- Corcept Therapeutics ↓ (BEARISH)▲
President of Oncology sold $2.63M in stock at ~$110.70 via a 10b5-1 plan. Combined with other insider awards, this suggests a planned distribution of shares to executives who are then selling.
- Senti Biosciences ↓ (MIXED)▲
Secured $4.5M in new financing (convertible notes + equity commitment) tied to a potential merger with a Celadon affiliate, including a $60M CVR for SENTI-202. This is a lifeline but signals significant financial distress.
- Rent the Runway ↓ (BEARISH)▲
Agreed to a $9M settlement for a class-action IPO lawsuit. While avoiding admission of liability, the $3.1M cash payment is material for a company of its size and signals ongoing legal overhang.
Risk Flags (10)
- Natera/Insider Selling↓ [HIGH RISK]▼
The President of Clinical Diagnostics sold $4.96M and the CEO sold $545K in a single day. This level of high-ranking insider selling is a major red flag for the stock's valuation.
- Spyre Therapeutics/Insider Liquidation↓ [HIGH RISK]▼
Three top executives (CEO, CFO, and another officer) sold a combined ~$3.8M in stock. The CFO's sale of 18,232 shares is particularly concerning as it represents a significant portion of his holdings.
- Takeda Pharmaceutical/R&D Chief Sale↓ [HIGH RISK]▼
The President of R&D sold 116,191 ADS for $2.15M. This is a massive sale by a key executive responsible for the pipeline, potentially signaling a lack of confidence in near-term drug prospects.
- Rent the Runway/Litigation Settlement↓ [HIGH RISK]▼
The $9M settlement for IPO-related securities claims is a material financial hit. The $3.1M cash component strains liquidity, and the stock component could dilute existing shareholders.
- Trade Desk/Restructuring Costs↓ [MEDIUM RISK]▼
The 15% workforce reduction will result in $39-51M in cash charges in Q3 2026. This will significantly impact near-term profitability and could signal underlying business challenges.
- Black Hawk Acquisition/SPAC Risk↓ [HIGH RISK]▼
The SPAC has seen 69.2% shareholder redemptions and is relying on $1.6M in sponsor loans to fund extensions. The proposed merger with Vesicor (preclinical, no revenue) is high-risk, and Nasdaq compliance is at stake.
- Senti Biosciences/Financial Distress↓ [HIGH RISK]▼
The company issued a high-interest convertible note (200% of principal at maturity) and secured an equity line, indicating severe cash burn and reliance on dilutive financing for survival.
- Corcept Therapeutics/Oncology President Sale↓ [MEDIUM RISK]▼
The President of Oncology sold $2.63M in stock, the largest insider transaction in the filing. This is a strong negative signal from a key business unit leader.
- Fold Holdings/Insider Sales↓ [MEDIUM RISK]▼
CEO, CFO, and CTO all sold shares at $0.46. While the dollar amounts are small, the coordinated selling by the entire C-suite at a low stock price is a negative sentiment indicator.
- RE/MAX Holdings/De-Listing↓ [HIGH RISK]▼
The company's deregistration following a merger is a finality risk for any remaining minority shareholders, as the stock will no longer be publicly traded.
Opportunities (8)
- Ionis Pharmaceuticals/ZANVASTRO Approval↓ (OPPORTUNITY)◆
The FDA approval for Alexander disease is a first-in-disease therapy, creating a monopoly in an ultra-rare market. The stock could re-rate significantly as revenue begins to flow, despite the mixed financial history.
- TransAct Technologies/Activist Catalyst↓ (OPPORTUNITY)◆
Activist investor Charles Gillman is pushing for a full sale of the company. With a 5.1% stake and a public campaign, the stock has a clear catalyst for a premium buyout, especially given the favorable micro-cap activism environment.
- Flex Ltd./Spin-Off Catalyst↓ (OPPORTUNITY)◆
The planned spin-off of SpinCo is a value-unlocking event. Shareholders will receive shares in a new, more focused entity, which could lead to a sum-of-the-parts re-rating.
- SK hynix/Solidigm Pre-IPO↓ (OPPORTUNITY)◆
The potential KRW 5 trillion pre-IPO for Solidigm is a major value unlock for SK hynix shareholders. A successful capital raise would validate the subsidiary's value and provide a clearer path to an IPO.
- Capstone Green Energy/Director Awards↓ (OPPORTUNITY)◆
Multiple directors were awarded voting common stock. This is a bullish signal from the board, aligning their interests with shareholders and indicating confidence in the company's future.
- Rome Wildlife/Insider Awards↓ (OPPORTUNITY)◆
Directors and officers were awarded significant stock grants (e.g., 601,998 shares to Director Carlson). This heavy insider equity grant suggests strong conviction in the company's long-term prospects.
- NatWest Group/PDMR Sales at Same Price↓ (OPPORTUNITY)◆
Three top PDMRs sold shares at the exact same price (£6.9023). While a sale, the uniformity suggests a pre-arranged plan, and the stock's ability to absorb the supply could be a sign of underlying strength.
- H World Group/CNY Bond Offering↓ (OPPORTUNITY)◆
The proposed CNY-denominated bond offering could provide a low-cost source of capital, especially if the company can tap into the onshore Chinese market at favorable rates.
Sector Themes (5)
- Biotech Insider Selling Wave◆
A clear pattern of insider selling is emerging in the biotech sector. Natera, Spyre Therapeutics, and Corcept Therapeutics all saw significant insider sales, suggesting that management teams are taking profits after recent rallies or are cautious on near-term prospects.
- Corporate Restructuring for Efficiency◆
The Trade Desk's 15% workforce reduction and Flex's spin-off highlight a trend of companies actively restructuring to improve focus and operational efficiency. This is a positive for long-term margins but creates near-term earnings noise.
- SPAC Distress and Lifelines◆
The Black Hawk Acquisition filing reveals the ongoing struggles in the SPAC market, with high redemptions (69.2%) and reliance on sponsor loans. Senti Biosciences' financing tied to a merger also shows the precarious state of many de-SPACed companies.
- Activist Pressure on Micro-Caps◆
The TransAct Technologies filing is a textbook example of a micro-cap activist campaign. The filing notes that AI-driven cost reductions are making such campaigns more viable, suggesting this could be a growing trend for undervalued small companies.
- Post-IPO Legal Overhang◆
The Rent the Runway settlement is a reminder of the legal risks for companies that went public during the 2020-2021 IPO boom. This could be a recurring theme as other class-action lawsuits from that era reach resolution.
Watch List (8)
-
Watch for initial sales data for ZANVASTRO and the timing of European/Japanese submissions (expected 2027). The Q3 2026 earnings call will be critical for revenue guidance. [Catalyst: Sep 2026+]
-
Monitor the Q3 2026 earnings report for details on the restructuring charges and any impact on revenue growth. The company's ability to re-accelerate growth post-restructuring is key. [Catalyst: Q3 2026 Earnings]
-
The deadline for Nasdaq compliance is September 28, 2026. Watch for shareholder vote on the Vesicor merger and any further redemptions. The SPAC's survival is at stake. [Catalyst: Sep 28, 2026]
-
The filing of the Form 10 registration statement for SpinCo will be a key catalyst, providing detailed financials and valuation for the new entity. [Catalyst: Pending]
-
Watch for a response from the company's board to Gillman's activist campaign. Any announcement of a strategic review or special meeting would be a major catalyst. [Catalyst: Near-term]
-
The company committed to further disclosure on Solidigm's capital raising within three months (by Dec 4, 2026). Any news of a deal would be a major positive catalyst. [Catalyst: Dec 4, 2026]
-
The merger with a Celadon affiliate and the associated $60M CVR are pending shareholder approval. The outcome of the vote is critical for the company's future. [Catalyst: Pending]
-
The settlement is subject to court approval. Monitor for any objections or delays that could prolong the legal overhang. [Catalyst: Pending Court Approval]
Filing Analyses
(50)
03-09-2026
See Remarks Lyon Joseph Douglas was awarded 130 Common Stock at $113.38 (~$14.7K). Lyon Joseph Douglas holds 5,683 shares after the transaction.
- · See Remarks Lyon Joseph Douglas was awarded 130 Common Stock at $113.38 (~$14.7K)
- · See Remarks Lyon Joseph Douglas was awarded 130 Common Stock
- · See Remarks Lyon Joseph Douglas had withheld for taxes 72 Common Stock at $113.38 (~$8.16K)
03-09-2026
Director PWP VoteCo Professionals LP disposed of 1,997,030 Class B-1 Common Stock at $0.02 (~$39.9K).
- · Director PWP VoteCo Professionals LP disposed of 1,997,030 Class B-1 Common Stock at $0.02 (~$39.9K)
03-09-2026
Chief Financial Officer Mokari Atabak was awarded 138 Common Stock at $113.38 (~$15.6K). Mokari Atabak holds 16,304 shares after the transaction.
- · Chief Financial Officer Mokari Atabak was awarded 138 Common Stock at $113.38 (~$15.6K)
- · Chief Financial Officer Mokari Atabak was awarded 138 Common Stock
- · Chief Financial Officer Mokari Atabak had withheld for taxes 102 Common Stock at $113.38 (~$11.6K)
03-09-2026
Director Wassenaar Yvonne sold 721 Class A Common Stock at $89.52 (~$64.5K). Wassenaar Yvonne holds 3,709 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director Wassenaar Yvonne exercised/converted 513 Class A Common Stock
- · Director Wassenaar Yvonne sold 721 Class A Common Stock at $89.52 (~$64.5K)
- · Director Wassenaar Yvonne exercised/converted 513 Class B Common Stock
03-09-2026
CEO AND PRESIDENT Chapman Steven Leonard sold 1,698 Common Stock at $320.99 (~$545K). Chapman Steven Leonard holds 98,199 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · CEO AND PRESIDENT Chapman Steven Leonard sold 1,698 Common Stock at $320.99 (~$545K)
03-09-2026
Chief Business Officer Robb Gary Charles was awarded 164 Common Stock at $113.38 (~$18.6K). Robb Gary Charles holds 13,663 shares after the transaction.
- · Chief Business Officer Robb Gary Charles was awarded 164 Common Stock at $113.38 (~$18.6K)
- · Chief Business Officer Robb Gary Charles was awarded 164 Common Stock
- · Chief Business Officer Robb Gary Charles had withheld for taxes 91 Common Stock at $113.38 (~$10.3K)
03-09-2026
President, Oncology Vieira Roberto Wandenkolk sold 23,770 Common Stock at $110.70 (~$2.63M). 12 transactions reported in total. Vieira Roberto Wandenkolk holds 4,242 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · President, Oncology Vieira Roberto Wandenkolk was awarded 138 Common Stock at $113.38 (~$15.6K)
- · President, Oncology Vieira Roberto Wandenkolk was awarded 138 Common Stock
- · President, Oncology Vieira Roberto Wandenkolk had withheld for taxes 102 Common Stock at $113.38 (~$11.6K)
- · President, Oncology Vieira Roberto Wandenkolk exercised/converted 58,333 Common Stock at $21.63 (~$1.26M)
- · President, Oncology Vieira Roberto Wandenkolk sold 23,600 Common Stock at $109.35 (~$2.58M)
- · President, Oncology Vieira Roberto Wandenkolk sold 23,770 Common Stock at $110.70 (~$2.63M)
- · President, Oncology Vieira Roberto Wandenkolk sold 1,537 Common Stock at $111.37 (~$171K)
- · President, Oncology Vieira Roberto Wandenkolk sold 974 Common Stock at $112.40 (~$109K)
03-09-2026
Dennis J. Wilson and affiliated entities collectively beneficially own 9,570,851 shares of lululemon athletica common stock (8.6% of total voting power), unchanged from prior filings. LIPO Investments (USA) entered into a two-year prepaid variable share forward transaction with Goldman Sachs covering 1,274,318 shares (~1.2% of outstanding stock and ~13.3% of the group's holdings) to boost liquidity, while retaining voting and economic rights. Wilson 5 Foundation sold 5,713 shares in open market on August 4, 2026 at $122.56 per share, representing a minimal reduction.
- · The Goldman Sachs Confirmation replaces an expired Master Confirmation (July 2026) that previously involved Low Tide Properties Ltd.
- · LIPO retains the ability to settle the forward transaction in cash, allowing it to keep full ownership of the pledged shares and participate in all future price appreciation.
- · No event of default or similar event has occurred under the Goldman Sachs Confirmation; voting and economic rights remain with LIPO so long as no default occurs.
- · House of Wilson Ltd. holds 0 shares.
03-09-2026
Bpifrance Participations SA and related entities (Bpifrance Investissement, Caisse des Depots, EPIC Bpifrance, Bpifrance S.A.) filed a Schedule 13D disclosing beneficial ownership of 24,480,841 ordinary shares of Pasqal Holding SA (formerly Bleichroeder Acquisition 2 France), representing 11.4% of the outstanding shares as of August 27, 2026. The stake was acquired through a business combination involving Bleichroeder Acquisition Corp. II and Pasqal Holding SAS, with Bpifrance Investissement also subscribing to $12.5 million in convertible bonds and warrants. The filing indicates a significant institutional investment in the quantum computing company, with board representation rights.
- · The Reporting Persons include Bpifrance Participations, Bpifrance Investissement, Caisse des Depots, EPIC Bpifrance, and Bpifrance S.A., all organized under French law.
- · Bpifrance Investissement has the right to designate one member of the Issuer's Board of Directors.
- · The convertible bonds and warrants were acquired using working capital.
- · The warrants are exercisable until August 27, 2031.
- · The business combination closed on or around August 27, 2026.
- · No criminal or civil securities law proceedings have been brought against the Reporting Persons in the last five years.
03-09-2026
Executive VP of R&D WIMMERS DIDIER had withheld for taxes 317 Common Stock at $76.27 (~$24.2K). WIMMERS DIDIER holds 12,379 shares after the transaction.
- · Executive VP of R&D WIMMERS DIDIER had withheld for taxes 317 Common Stock at $76.27 (~$24.2K)
03-09-2026
Chief Development Officer Guyer William was awarded 164 Common Stock at $113.38 (~$18.6K). Guyer William holds 4,313 shares after the transaction.
- · Chief Development Officer Guyer William was awarded 164 Common Stock at $113.38 (~$18.6K)
- · Chief Development Officer Guyer William was awarded 164 Common Stock
03-09-2026
See Remarks Maduck Sean sold 11,730 Common Stock at $113.94 (~$1.34M). 8 transactions reported in total. Maduck Sean holds 9,938 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · See Remarks Maduck Sean exercised/converted 25,000 Common Stock at $8.27 (~$207K)
- · See Remarks Maduck Sean sold 11,730 Common Stock at $113.94 (~$1.34M)
- · See Remarks Maduck Sean sold 10,989 Common Stock at $114.71 (~$1.26M)
- · See Remarks Maduck Sean sold 2,281 Common Stock at $115.61 (~$264K)
- · See Remarks Maduck Sean was awarded 150 Common Stock at $113.38 (~$17K)
- · See Remarks Maduck Sean was awarded 150 Common Stock
- · See Remarks Maduck Sean had withheld for taxes 117 Common Stock at $113.38 (~$13.3K)
- · See Remarks Maduck Sean exercised/converted 25,000 Stock option (right to buy)
03-09-2026
Chief Technology Officer Dickman Thomas J sold 6 Common Stock at $0.46 (~$2.74). 4 transactions reported in total. Dickman Thomas J holds 541,718 shares after the transaction.
- · Chief Technology Officer Dickman Thomas J was awarded 5,000 Common Stock
- · Chief Technology Officer Dickman Thomas J exercised/converted 17 Common Stock
- · Chief Technology Officer Dickman Thomas J sold 6 Common Stock at $0.46 (~$2.74)
- · Chief Technology Officer Dickman Thomas J exercised/converted 17 Restricted Stock Units
03-09-2026
Chief Executive Officer Reeves William Brian Poppic sold 5,288 Common Stock at $0.46 (~$2.42K). 6 transactions reported in total. Reeves William Brian Poppic holds 5,438,928 shares after the transaction.
- · Chief Executive Officer Reeves William Brian Poppic exercised/converted 1,075 Common Stock
- · Chief Executive Officer Reeves William Brian Poppic exercised/converted 11,549 Common Stock
- · Chief Executive Officer Reeves William Brian Poppic sold 5,288 Common Stock at $0.46 (~$2.42K)
- · Chief Executive Officer Reeves William Brian Poppic sold 493 Common Stock at $0.46 (~$225)
- · Chief Executive Officer Reeves William Brian Poppic exercised/converted 1,075 Restricted Stock Units
- · Chief Executive Officer Reeves William Brian Poppic exercised/converted 11,549 Restricted Stock Units
03-09-2026
Chief Financial Officer Repass Wolfe sold 844 Common Stock at $0.46 (~$386). 9 transactions reported in total. Repass Wolfe holds 737,150 shares after the transaction.
- · Chief Financial Officer Repass Wolfe exercised/converted 2,639 Common Stock
- · Chief Financial Officer Repass Wolfe exercised/converted 17 Common Stock
- · Chief Financial Officer Repass Wolfe exercised/converted 1,539 Common Stock
- · Chief Financial Officer Repass Wolfe sold 5 Common Stock at $0.46 (~$2.29)
- · Chief Financial Officer Repass Wolfe sold 844 Common Stock at $0.46 (~$386)
- · Chief Financial Officer Repass Wolfe sold 493 Common Stock at $0.46 (~$225)
- · Chief Financial Officer Repass Wolfe exercised/converted 2,639 Restricted Stock Units
- · Chief Financial Officer Repass Wolfe exercised/converted 17 Restricted Stock Units
03-09-2026
Director Jenkins Norman K. was awarded 10,079 Common Stock, par value $0.001 per share. This amends a previously filed Form 4. Jenkins Norman K. holds 10,079 shares after the transaction.
- · Director Jenkins Norman K. was awarded 10,079 Common Stock, par value $0.001 per share
03-09-2026
Director Close Christopher J. was awarded 5,357 Voting Common Stock. Close Christopher J. holds 24,238 shares after the transaction.
- · Director Close Christopher J. was awarded 5,357 Voting Common Stock
03-09-2026
President, R&D Plump Andrew Stewart sold 116,191 American Depositary Shares at $18.49 (~$2.15M). Plump Andrew Stewart holds 145,465 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · President, R&D Plump Andrew Stewart sold 116,191 American Depositary Shares at $18.49 (~$2.15M)
03-09-2026
Chairman & CEO Sridhar KR exercised/converted 9,688 Common Stock at $30.96 (~$300K). Sridhar KR holds 2,291,508 shares after the transaction.
- · Chairman & CEO Sridhar KR gifted 300,000 Common Stock
- · Chairman & CEO Sridhar KR exercised/converted 9,688 Common Stock at $30.96 (~$300K)
- · Chairman & CEO Sridhar KR exercised/converted 9,688 Stock Option (right to buy)
03-09-2026
Global Chief Financial Officer Drucker Mann Lindsay sold 7,717 Class A ordinary shares at $15.09 (~$116K). 6 transactions reported in total. Drucker Mann Lindsay holds 116,135 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Global Chief Financial Officer Drucker Mann Lindsay exercised/converted 7,717 Class A ordinary shares at $9.39 (~$72.5K)
- · Global Chief Financial Officer Drucker Mann Lindsay sold 7,717 Class A ordinary shares at $15.09 (~$116K)
- · Global Chief Financial Officer Drucker Mann Lindsay exercised/converted 809 Class A ordinary shares at $9.39 (~$7.6K)
- · Global Chief Financial Officer Drucker Mann Lindsay sold 809 Class A ordinary shares at $15.01 (~$12.1K)
- · Global Chief Financial Officer Drucker Mann Lindsay exercised/converted 7,717 Stock Option (Right to Buy)
- · Global Chief Financial Officer Drucker Mann Lindsay exercised/converted 809 Stock Option (Right to Buy)
03-09-2026
Director SHERWIN STEPHEN A gifted 1,000 Common Stock. SHERWIN STEPHEN A holds 14,860 shares after the transaction.
- · Director SHERWIN STEPHEN A gifted 1,000 Common Stock
03-09-2026
Director LEIDEL PETER A disposed of 1,000,000 Class A Common Stock, par value $0.01 per share. LEIDEL PETER A holds 151,535 shares after the transaction.
- · Director LEIDEL PETER A disposed of 1,000,000 Class A Common Stock, par value $0.01 per share
- · Director LEIDEL PETER A acquired 46,777 Class A Common Stock, par value $0.01 per share
03-09-2026
PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 15,160 Common Stock at $326.89 (~$4.96M). 4 transactions reported in total. Moshkevich Solomon holds 110,859 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 1,000 Common Stock at $319.76 (~$320K)
- · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 1,400 Common Stock at $320.92 (~$449K)
- · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 600 Common Stock at $321.91 (~$193K)
- · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 15,160 Common Stock at $326.89 (~$4.96M)
03-09-2026
See Remarks King-Jones Heidy sold 16,548 Common Stock at $87.20 (~$1.44M). 9 transactions reported in total. King-Jones Heidy holds 2,845 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · See Remarks King-Jones Heidy exercised/converted 27,999 Common Stock at $14.50 (~$406K)
- · See Remarks King-Jones Heidy sold 4,845 Common Stock at $86.40 (~$419K)
- · See Remarks King-Jones Heidy sold 16,548 Common Stock at $87.20 (~$1.44M)
- · See Remarks King-Jones Heidy sold 6,206 Common Stock at $88.17 (~$547K)
- · See Remarks King-Jones Heidy sold 400 Common Stock at $89.38 (~$35.8K)
- · See Remarks King-Jones Heidy exercised/converted 400 Common Stock at $14.50 (~$5.8K)
- · See Remarks King-Jones Heidy sold 400 Common Stock at $90.00 (~$36K)
- · See Remarks King-Jones Heidy exercised/converted 27,999 Stock Option (Right to Buy)
03-09-2026
Chief Financial Officer Burrows Scott L sold 18,232 Common Stock at $89.35 (~$1.63M). 7 transactions reported in total. Burrows Scott L holds 79,762 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Financial Officer Burrows Scott L exercised/converted 7,500 Common Stock at $14.50 (~$109K)
- · Chief Financial Officer Burrows Scott L sold 900 Common Stock at $86.25 (~$77.6K)
- · Chief Financial Officer Burrows Scott L sold 4,384 Common Stock at $87.11 (~$382K)
- · Chief Financial Officer Burrows Scott L sold 2,016 Common Stock at $88.03 (~$177K)
- · Chief Financial Officer Burrows Scott L sold 200 Common Stock at $89.04 (~$17.8K)
- · Chief Financial Officer Burrows Scott L sold 18,232 Common Stock at $89.35 (~$1.63M)
- · Chief Financial Officer Burrows Scott L exercised/converted 7,500 Stock Option (Right to Buy)
03-09-2026
Chief Executive Officer Turtle Cameron sold 8,400 Common Stock at $87.15 (~$732K). 4 transactions reported in total. Turtle Cameron holds 552,540 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Executive Officer Turtle Cameron sold 2,500 Common Stock at $86.36 (~$216K)
- · Chief Executive Officer Turtle Cameron sold 8,400 Common Stock at $87.15 (~$732K)
- · Chief Executive Officer Turtle Cameron sold 3,700 Common Stock at $88.06 (~$326K)
- · Chief Executive Officer Turtle Cameron sold 400 Common Stock at $89.07 (~$35.6K)
03-09-2026
Director Lawrence Bryan H. disposed of 1,000,000 Class A Common Stock, par value $0.01 per share. Lawrence Bryan H. holds 253,689 shares after the transaction.
- · Director Lawrence Bryan H. disposed of 1,000,000 Class A Common Stock, par value $0.01 per share
- · Director Lawrence Bryan H. acquired 88,135 Class A Common Stock, par value $0.01 per share
03-09-2026
Charles M. Gillman, through IDWR Office, disclosed a 5.1% stake in TransAct Technologies Inc (TACT) and is publicly urging the company to sell both its slot-machine printer business and its BOHA! restaurant technology software business, effectively calling for a full sale of the company. Gillman believes the company is undervalued and that its BOHA! business faces unique challenges requiring an immediate strategic review and board refreshment. The activist campaign comes amid a favorable environment for micro-cap activism, with AI-driven cost reductions making such campaigns economically viable for smaller companies.
- · Gillman purchased shares on 07-01-2026 (62,064 shares at $5.80), 06-30-2026 (37,936 shares at $5.76), and 06-29-2026 (1,603 shares at $5.21).
- · Gillman has no specific plan to acquire or dispose of additional shares but may do so based on market conditions.
- · Gillman believes shareholders holding a majority of voting rights can call a special meeting to elect additional board members.
- · IDWR Office is a single-family office with no external investors; activism is one of three investment strategies.
- · Gillman typically targets companies where misaligned compensation, weak governance, flawed business models, or missed strategic opportunities have suppressed value.
03-09-2026
CFO and Corporate Secretary WOLSFELD MATTHEW C was awarded 29,755 Stock Option (right to buy).
- · CFO and Corporate Secretary WOLSFELD MATTHEW C was awarded 29,755 Stock Option (right to buy)
03-09-2026
Director Powelson Robert F was awarded 5,357 Voting Common Stock. Powelson Robert F holds 60,795 shares after the transaction.
- · Director Powelson Robert F was awarded 5,357 Voting Common Stock
- · Director Powelson Robert F was awarded 0 Non-voting Common Stock
03-09-2026
Director Carlson Erik was awarded 601,998 Common Stock, par value $0.001 per share. 7 transactions reported in total. Carlson Erik holds 458,185 shares after the transaction.
- · Director Carlson Erik was awarded 601,998 Common Stock, par value $0.001 per share
- · Director Carlson Erik had withheld for taxes 263,369 Common Stock, par value $0.001 per share
- · Director Carlson Erik disposed to the issuer 33,227 Restricted Share Unit
- · Director Carlson Erik disposed to the issuer 87,864 Restricted Share Unit
- · Director Carlson Erik disposed to the issuer 184,221 Restricted Share Unit
- · Director Carlson Erik disposed to the issuer 112,465 Restricted Share Unit
- · Director Carlson Erik disposed to the issuer 184,221 Restricted Share Unit
03-09-2026
Director Carlson Erik was awarded 119,556 Common Stock, par value $0.001 per share. This amends a previously filed Form 4. 6 transactions reported in total. Carlson Erik holds 119,556 shares after the transaction.
- · Director Carlson Erik was awarded 119,556 Common Stock, par value $0.001 per share
- · Director Carlson Erik was awarded 33,227 Restricted Share Unit
- · Director Carlson Erik was awarded 87,864 Restricted Share Unit
- · Director Carlson Erik was awarded 184,221 Restricted Share Unit
- · Director Carlson Erik was awarded 112,465 Restricted Share Unit
- · Director Carlson Erik was awarded 184,221 Restricted Share Unit
03-09-2026
Director Miller John P. was awarded 5,357 Voting Common Stock. Miller John P. holds 57,164 shares after the transaction.
- · Director Miller John P. was awarded 5,357 Voting Common Stock
03-09-2026
Director RAFFAELI C CATHLEEN was awarded 9,082 Common Stock, par value $0.001 per share. This amends a previously filed Form 4. RAFFAELI C CATHLEEN holds 14,430 shares after the transaction.
- · Director RAFFAELI C CATHLEEN was awarded 9,082 Common Stock, par value $0.001 per share
- · Director RAFFAELI C CATHLEEN was awarded 5,348 Common Stock, par value $0.001 per share
03-09-2026
Chief Accounting Officer Jenkins Leah R was awarded 4,508 Common Stock, par value $0.001 per share. This amends a previously filed Form 4. 7 transactions reported in total. Jenkins Leah R holds 4,508 shares after the transaction.
- · Chief Accounting Officer Jenkins Leah R was awarded 4,508 Common Stock, par value $0.001 per share
- · Chief Accounting Officer Jenkins Leah R was awarded 1,807 Restricted Share Units
- · Chief Accounting Officer Jenkins Leah R was awarded 3,420 Restricted Share Units
- · Chief Accounting Officer Jenkins Leah R was awarded 7,532 Restricted Share Units
- · Chief Accounting Officer Jenkins Leah R was awarded 4,282 Restricted Share Units
- · Chief Accounting Officer Jenkins Leah R was awarded 4,378 Restricted Share Units
- · Chief Accounting Officer Jenkins Leah R was awarded 7,532 Restricted Share Units
04-09-2026
Enigmatig Ltd (EGG) filed an F-3 shelf registration statement with the SEC on September 4, 2026, to register an unspecified amount of securities for future offerings. The company is a Cayman Islands exempted company with a dual-class share structure (Class A: 1 vote per share; Class B: 10 votes per share) and authorized share capital of US$50,000 divided into 25 billion shares. The filing does not disclose any specific offering terms, use of proceeds, or financial results, and incorporates by reference its most recent Annual Report on Form 20-F and subsequent Form 6-K filings.
- · The company was incorporated in the Cayman Islands on May 30, 2023.
- · No equity incentive plan or share-based compensation arrangement has been adopted.
- · Class B ordinary shares carry 10 votes per share and are convertible into Class A ordinary shares at the holder's option; Class A shares cannot be converted into Class B.
- · The company relies on home country practice to exempt itself from NYSE American corporate governance requirements, including the independence of a majority of directors.
- · Shareholders holding at least one-third of voting rights can requisition an extraordinary general meeting.
- · The company is not obliged to hold annual general meetings under Cayman Islands law.
- · Dividends may be paid out of profit or share premium account, subject to solvency conditions.
- · Variation of class rights requires consent of holders of at least two-thirds of the issued shares of that class.
04-09-2026
NatWest Group plc disclosed that three PDMRs (including the CEO, CFO, and Retail CEO) sold a total of 391,000 shares on 2 September 2026 at £6.9023 per share. The transactions represent routine insider sales and do not indicate any change in corporate strategy or financial outlook.
- · All three PDMRs sold shares at the same price of £6.9023 per share on the same date (2 September 2026).
- · Paul Thwaite (CEO) sold the most shares: 260,000.
- · Katie Murray (CFO) sold 111,000 shares.
- · Solange Chamberlain (Retail CEO) sold 20,000 shares.
04-09-2026
Black Hawk Acquisition Corp filed an S-4/A registration statement with the SEC on September 3, 2026, in connection with its proposed business combination with Vesicor Therapeutics, a preclinical-stage biopharmaceutical company. The filing details shareholder voting procedures, redemption rights, and the company's ongoing efforts to regain compliance with Nasdaq's minimum market value of listed securities requirement. Black Hawk has experienced significant shareholder redemptions (69.2% of public shares) and is relying on sponsor loans to fund monthly extension payments, while Vesicor remains in early development with no approved products.
- · Black Hawk received a Nasdaq MVLS deficiency notice on March 31, 2026, with a compliance deadline of September 28, 2026.
- · The company has issued five convertible notes to its sponsor since June 2025, totaling $1.6 million in principal, to fund monthly extension payments.
- · Vesicor is a preclinical-stage biopharmaceutical company with no approved products and limited business activities beyond R&D.
- · Shareholders who fail to vote but do not redeem will become stockholders of PubCo if the business combination is approved.
04-09-2026
Flex Ltd. filed a DEFA14A (additional proxy materials) on September 4, 2026, in connection with its proposed spin-off of a new entity (SpinCo). The filing urges shareholders to read the forthcoming proxy statement and Form 10 registration statement for important details about the spin-off, and identifies Flex's directors and executive officers as potential participants in the proxy solicitation. No financial results or period-over-period comparisons are included in this filing.
- · Flex intends to file a proxy statement on Schedule 14A and a Form 10 registration statement for SpinCo's common stock.
- · The proxy statement for Flex's 2026 annual meeting (filed June 24, 2026) contains information about directors and executive officers and their ownership of Flex ordinary shares.
- · Changes in holdings of Flex securities by directors and executive officers since the 2026 proxy statement will be reflected in subsequent Form 3 or Form 4 filings.
04-09-2026
The Trade Desk announced a workforce reduction of approximately 15% as part of an organizational realignment to focus on high-priority growth opportunities and improve operational efficiency. The company expects to incur cash restructuring charges of $39 million to $51 million in Q3 2026, partially offset by a reversal of $4 million to $5 million in stock-based compensation. While the restructuring aims to position the company for long-term growth, it involves significant near-term costs and workforce reductions.
- · The workforce reduction will be substantially completed during Q3 2026.
- · The company may incur additional charges or cash expenditures not currently contemplated due to unanticipated events.
- · The company will file an amended 8-K if amounts differ materially from estimates.
04-09-2026
United Microelectronics Corporation (UMC) filed a Form 6-K with the SEC on September 4, 2026, as a routine foreign issuer report. The filing was signed by CFO Chitung Liu and contains no financial results, material events, or operational updates beyond the standard regulatory submission.
04-09-2026
RE/MAX Holdings, Inc. filed Form 15 with the SEC on September 4, 2026, to terminate its registration and suspend its duty to file reports under Section 12(g) of the Securities Exchange Act of 1934. This action follows the completion of a merger on August 24, 2026, whereby the company was acquired by Real REMAX Group Inc. and its shareholders received cash for their shares, resulting in zero holders of record of Class A Common Stock.
- · The merger agreement was entered into on April 26, 2026 and amended on June 12, 2026.
- · The first merger (Merger Sub I into the Company) and subsequent merger (Company into Merger Sub II) both occurred on August 24, 2026.
- · The resulting entity, Wildlife Acquisition II LLC, is a wholly owned subsidiary of Real REMAX Group Inc.
- · The principal executive offices of the registrant are located at c/o Real REMAX Group Inc., 701 Brickell Avenue, 17th Floor, Miami, Florida 33131.
- · The Form 15 certification was signed by Leah Jenkins, Chief Accounting Officer.
04-09-2026
SK hynix Inc. issued a Form 6-K to clarify a media report that its U.S. subsidiary Solidigm is pursuing a pre-IPO capital raising of approximately KRW 5 trillion. The company states that while Solidigm is reviewing various measures to strengthen competitiveness, no definitive matters have been determined as of the filing date. SK hynix will provide further disclosure either when specific details are confirmed or within three months.
- · The clarification follows a similar disclosure on August 6, 2026.
- · No definitive decision has been made regarding Solidigm's capital raising as of September 4, 2026.
- · The company commits to further disclosure within three months if no specific details are confirmed earlier.
04-09-2026
Senti Biosciences Holdings, Inc. completed the issuance of $2.0 million in Senior Secured Convertible Notes to NSG BioInnovation Fund and entered into an equity commitment letter with an affiliate of Celadon Partners for $2.5 million in common stock, both on September 3, 2026. These financings are tied to a potential merger with a Celadon affiliate, which may also involve a contingent value right of up to $60.0 million based on SENTI-202 milestones. The company has filed a preliminary proxy statement for stockholder approval of these transactions, but no financial results or operational metrics are disclosed in this filing.
- · The Notes were issued under a Securities Purchase Agreement dated April 27, 2026, as amended on September 1, 2026.
- · The equity commitment letter with Celadon affiliate includes a purchase price equal to the 'Minimum Price' under Nasdaq Listing Rule 5635(d).
- · The contingent value right could pay up to $60.0 million in cash upon achievement of regulatory and sales milestones for SENTI-202.
- · A preliminary proxy statement on Schedule 14A was filed with the SEC on July 21, 2026, regarding the Subject Transactions.
- · The company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.
04-09-2026
Ionis Pharmaceuticals announced on September 3, 2026, that the FDA approved ZANVASTRO (zilganersen) for Alexander disease (AxD) in pediatric and adult patients, making it the first disease-modifying treatment for this ultra-rare disorder. The approval was based on a Phase 3 study that met its primary endpoint (gait speed stabilization, p=0.041) and showed a favorable safety profile; however, the approval also carried a Priority Review Voucher, and U.S. availability is weeks away, while regulatory submissions in Europe and Japan are expected in 2027. The company recorded a 9.3% year-over-year revenue decline in Q3 2025, with full‑year 2025 revenue down 12% and Q4 2025 revenue flat, reflecting ongoing transition to commercial-stage products.
- · ZANVASTRO 50 mg is administered quarterly as an intrathecal injection.
- · AxD affects approximately 1 in 1 to 3 million people worldwide.
- · The Phase 3 trial achieved statistically significant stabilization of gait speed (10-Meter Walk Test) at Week 61 (p=0.041).
- · Serious treatment-emergent adverse events occurred less frequently in the ZANVASTRO group than in control.
- · Ionis has licensed ex-U.S. rights to Recordati (Italy); regulatory submissions in Europe and Japan expected in 2027.
- · Product revenue from SPINRAZA royalties was flat in Q4 2025 at $97 million.
- · Full-year 2025 revenue declined 12% to $730 million, reflecting loss of U.S. SPINRAZA royalties after the patent settlement.
04-09-2026
H World Group Limited announced a proposed offering of CNY-denominated bonds on September 4, 2026. The filing is a Form 6-K submitted to the SEC, with the bond offering details to be provided in Exhibit 99.1. No financial figures or performance metrics were disclosed in this preliminary announcement.
- · The bond offering is denominated in Chinese Yuan (CNY).
- · The filing was made for the month of September 2026.
- · The registrant's principal executive office is located at No. 1299 Fenghua Road, Jiading District, Shanghai, People's Republic of China.
04-09-2026
Noah Holdings Limited filed a Form 6-K with the SEC for September 2026, attaching a monthly return on movements in securities for equity issuers and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. The filing is a routine regulatory disclosure and does not contain any financial results, material events, or operational updates.
04-09-2026
Flex Ltd. has filed a preliminary proxy statement (DEFA14A) in connection with a proposed spin-off of a subsidiary (SpinCo). The filing urges shareholders to read the proxy statement and Form 10 registration statement when available, as they contain important information about the transaction. The filing also identifies certain directors and executive officers as potential participants in the proxy solicitation.
- · The proxy statement for the 2026 annual meeting was filed on June 24, 2026.
- · The spin-off proposal requires shareholder approval via proxy vote.
- · A Form 10 registration statement for SpinCo's common stock is expected to be filed with the SEC.
- · Potential participants in the solicitation include Flex's directors and executive officers, with their holdings detailed in prior filings.
04-09-2026
Senti Biosciences, Inc. (SNTI) disclosed a Senior Secured Convertible Note issued by its subsidiary Senti Holdings, Inc. The note has a maturity date of November 23, 2026, and requires the company to pay 200% of outstanding principal plus accrued interest at maturity. Interest only accrues at a 12% default rate upon an event of default, and the note is exchangeable into shares of Issuer Common Stock at the holder's option.
- · Maturity date is November 23, 2026, extendable by the holder upon an event of default or change of control.
- · Interest accrues only after an event of default at 12% per annum (Default Rate).
- · The note is exchangeable into shares of Issuer Common Stock at any time before maturity.
- · The company must use a transfer agent that participates in DTC's Fast Automated Securities Transfer Program while notes are outstanding.
- · No specific principal amount was disclosed in this exhibit; the filing is a form of note with placeholder values.
04-09-2026
Rent the Runway, Inc. has entered into a Stipulation and Agreement of Settlement to resolve a putative class action lawsuit related to its IPO, agreeing to pay a total settlement consideration of $9,000,000. The settlement consists of $6,000,000 in cash (with $3,100,000 from the company and $2,900,000 from insurers) and $3,000,000 in Class A common stock (or cash at the company's discretion). The settlement is subject to court approval and involves no admission of liability, but represents a material financial obligation for the company.
- · Lawsuit filed on November 14, 2022 in Eastern District of New York (Case No. 22-cv-6935)
- · Allegations under Sections 11 and 15 of the Securities Act of 1933 regarding misleading statements and omissions about company growth at IPO
- · Settlement is without admission of liability, wrongdoing, damages, negligence, or fault
- · Settlement requires both preliminary and final approval by the District Court
- · Company may, in its sole discretion, pay all or a portion of the $3,000,000 stock component in cash instead
Get daily alerts with 10 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Pre-Market SEC Filings Roundup
🇺🇸 More from United States
View all →September 05, 2026
New Federal Contractors — September 05, 2026
New Federal Contractors
September 05, 2026
Significant Contract Modifications ($10M+) — September 05, 2026
Significant Contract Modifications ($10M+)
September 05, 2026
NASA & Space Contracts Intelligence — September 05, 2026
NASA & Space Contracts Intelligence
September 05, 2026
High-Value Federal Grants ($5M+) — September 05, 2026
High-Value Federal Grants ($5M+)